Suzuki T, Moriya T, Sugawara A, Ariga N, Takabayashi H, Sasano H
Department of Pathology, Tohoku University School of Medicine, Sendai, Japan.
Breast Cancer Res Treat. 2001 Jan;65(1):31-40. doi: 10.1023/a:1006433929792.
Retinoid receptors (retinoic acid (RARs) and retinoid X (RXRs) receptors) were immunolocalized in 32 human invasive ductal breast carcinomas. These findings were correlated with clinicopathological parameters to study their biological significance in breast carcinoma. Retinoid receptor immunoreactivity, except for RXRgamma, was detected in the nuclei of carcinoma cells. Percentage of positive cases were RARalpha; 81%, RARbeta; 6%, RARgamma; 28%, RXRalpha; 81%, and RXRbeta; 59%. A significant correlation was detected between RARalpha labeling index (LI), and RXRalpha LI (r = 0.667, p < 0.001). Results from immunoblotting performed in three cases were consistent with those of immunohistochemistry. There was a significant correlation between RARalpha LI and 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 1 immunoreactivity (p < 0.05). A significant correlation was also detected between RARalpha (r= 0.413, p = 0.019) or RXRalpha (r = 0.429, p = 0.014) LI, and estrogen receptor (ER) LI. In T-47D breast cancer cells, which express RARalpha, RXRalpha and ER, 17beta-HSD reductive activity increased 1.76-fold (p < 0.001), five days following treatment with 10 nM retinoic acid. These data suggest that retinoid receptors modulate various effects of retinoids, including estrogen metabolism in human breast carcinomas.
